Get alerted when Policy PG152 changes without checking for updates manually.
Monitor payer policy activity
Receive email alerts as soon as relevant payer policies are published or updated.
This guideline governs medical necessity and prior authorization for GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists used to treat type 2 diabetes mellitus, including initial and continued therapy. Other indications, such as weight management, cardiovascular risk reduction, and obstructive sleep apnea, are addressed under separate Oscar guidelines.
Key ActionSubmit documentation showing the member meets the applicable type 2 diabetes criteria, including diagnostic results, prior therapy, clinical response, and absence of prohibited concurrent therapy.
No material clinical or coverage changes in this revision.
12 monthsMaximum approval period
≥6.5%HbA1c diagnostic threshold
1500 mg/90 daysMinimum metformin trial
≥15CKD pathway eGFR threshold
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.
Not allowedConcurrent GLP-1 therapy
Coverage Criteria
Initial therapy for type 2 diabetes mellitus
Covered when ALL of the following are met for type 2 diabetes mellitus.
Initial therapy
Age appropriateness: For Bydureon BCise (exenatide), Mounjaro (tirzepatide), Trulicity (dulaglutide), or Victoza (liraglutide), the member is at least 10 years old; for other GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists, the member is at least 18 years old.10 or 18 years, depending on product
Must follow FDA-approved age indications.
Type 2 diabetes diagnosis: At least one accepted diagnostic criterion is present.Fasting plasma glucose ≥126 mg/dL (≥7.0 mmol/L); 2-hour glucose tolerance test ≥200 mg/dL (≥11.1 mmol/L); HbA1c ≥6.5% (≥48 mmol/mol); or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemia symptoms or hyperglycemic crisis.
The random-glucose pathway requires classic symptoms or hyperglycemic crisis.
Qualifying treatment or comorbidity pathway
Metformin or glycemic-control pathway: The member cannot use metformin or has adequately tried and failed metformin at a minimum effective dose of 1500 mg daily for at least 90 days; or combination therapy is required to achieve glycemic control and HbA1c is ≥7.5%.Metformin 1500 mg daily for at least 90 days; HbA1c ≥7.5%
State mandates may apply to the metformin requirement.
Established ASCVD pathway: The member has established ASCVD and the request is for liraglutide (Victoza), Ozempic (semaglutide) injection, Rybelsus/Ozempic pill (semaglutide), or Trulicity (dulaglutide).
ASCVD examples include coronary artery disease, cerebrovascular disease, and peripheral arterial disease.
Multiple cardiovascular-risk-factor pathway: The member has at least two cardiovascular risk factors and the request is for Trulicity (dulaglutide) or Rybelsus/Ozempic pill (semaglutide).2 or more risk factors
No prohibited combination with DPP-4 therapy: The member is not receiving a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist with a DPP-4 inhibitor or DPP-4 antidiabetic combination.
No duplicate GLP-1-based therapy: The requested medication will not be used concomitantly with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.
Continuation therapy for type 2 diabetes mellitus
Covered for continued therapy when ALL of the following are met.
Continuation therapy
Documented response or qualifying benefit: At least one of the following is present: HbA1c reduction since therapy initiation documented within the past 6 months; attainment of target HbA1c, such as less than 7% or a member-specific goal; improvement in fasting plasma glucose or another individualized glycemic target such as average glucose, preprandial or postprandial glucose, or CGM time in range; or established ASCVD, multiple cardiovascular risk factors, or CKD with a requested agent having proven benefit.HbA1c less than 7% is an example target; response documentation within the past 6 months
Agents with proven benefits are liraglutide (Victoza), Ozempic (semaglutide) injection, Rybelsus/Ozempic pill (semaglutide), and Trulicity (dulaglutide).
No prohibited combination with DPP-4 therapy: The member is not receiving a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist with a DPP-4 inhibitor or DPP-4 antidiabetic combination.
Continued care for type 2 diabetes mellitus
Covered for continued therapy when ALL of the following are met.
Continued therapy requirements
Qualifying clinical benefit
HbA1c reduction: Reduction in HbA1c since initiation of therapy is documented within the past 6 months.Within the past 6 months
Target HbA1c attained: The member has attained target HbA1c levels.For example, HbA1c less than 7% or a treating-provider-defined member-specific goal
Improved glycemic control
Use of GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists for indications other than type 2 diabetes mellitus is excluded from coverage under this guideline.
This guideline does not address obesity treatment, weight loss or weight reduction, dietary control, cardiovascular risk reduction, MASH, or obstructive sleep apnea. These indications are managed under separate Oscar guidelines, including PG070, PG194, PG255, and PG276, as applicable.
The requested medication must not be used concomitantly with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist. The member also must not receive GLP-1-based therapy in combination with a DPP-4 inhibitor or DPP-4 antidiabetic combination.
This guideline is limited to GLP-1-based therapy for type 2 diabetes mellitus. Coverage criteria for non-type 2 diabetes indications are addressed separately, including weight management under PG070, cardiovascular risk reduction or MASH under PG194, and obstructive sleep apnea under PG255 or PG276 for New York members.
Any other indication, including an unrecognized “type 1.5” diabetes mellitus designation, is considered experimental, investigational, or unproven and is not medically necessary under this guideline.
Use of GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists for an indication other than type 2 diabetes mellitus is considered experimental, investigational, unproven, and not medically necessary under this guideline.
The designation “type 1.5 diabetes” is not recognized by the cited American Diabetes Association Standard of Care. Members may have features of both type 1 and type 2 diabetes, but the prescriber must determine the member’s appropriate primary diabetes diagnosis.
Initial Therapy Criteria
Initial therapy
Initial therapy is medically necessary when ALL applicable criteria are met.
Initial drug authorization
Age appropriateness: For Bydureon BCise, Mounjaro, Trulicity, or Victoza, the member is at least 10 years old; for other GLP-1 or dual GIP/GLP-1 agents, the member is at least 18 years old.10 or 18 years, depending on product
Type 2 diabetes diagnostic criterion: At least one accepted diagnostic criterion is present: fasting plasma glucose ≥126 mg/dL, 2-hour glucose tolerance test ≥200 mg/dL, HbA1c ≥6.5%, or random plasma glucose ≥200 mg/dL with classic hyperglycemia symptoms or hyperglycemic crisis.
Qualifying treatment or comorbidity pathway
Continuation Criteria
Subsequent therapy
Continued therapy is medically necessary when ALL of the following are met.
Continuation criteria: The member demonstrates glycemic improvement, reaches a target HbA1c, or has ASCVD, multiple cardiovascular risk factors, or CKD with a requested agent having proven benefit; the member is not receiving the therapy with a DPP-4 inhibitor or DPP-4 combination; and the requested medication will not be used with another GLP-1-based therapy.
Approval is for up to 12 months when criteria are met.
Type 2 diabetes continued care
Continued therapy is medically necessary when all listed requirements are met.
Continued therapy
Qualifying clinical benefit
HbA1c reduction:
Diagnostic and Treatment Thresholds
Coding
Diagnostic threshold≥126 mg/dL (≥7.0 mmol/L)
TestFasting plasma glucose
UseOne accepted criterion for diagnosing type 2 diabetes mellitus
Coding
Diagnostic threshold≥200 mg/dL (≥11.1 mmol/L)
Test2-hour glucose tolerance test
UseOne accepted criterion for diagnosing type 2 diabetes mellitus
Authorization, Documentation, and Denial Conditions
Step Therapy
Preferred Medication Prerequisite
Before requesting a non-preferred or non-formulary GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist, document that the member is unable to use the preferred medication(s) or has tried and failed them. Non-formulary requests are also subject to the Non-Formulary Products Criteria (PG069).
Confirm preferred-medication prerequisite before submitting the request.
Apply PG069 for non-formulary products.
Prior Authorization
Initial Authorization Requirements
Submit the initial authorization request for type 2 diabetes only when all medical-necessity requirements are met. The requested medication must be age-appropriate, the member must meet an accepted diagnostic criterion for type 2 diabetes, and the member must meet at least one qualifying treatment-pathway criterion.
Age requirement: at least 10 years for Bydureon BCise, Mounjaro, Trulicity, or Victoza; at least 18 years for other GLP-1 or dual GIP/GLP-1 agents.
Clinical Background
GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are incretin-based antidiabetic therapies used to improve glycemic control in type 2 diabetes mellitus. Under this guideline, their use is evaluated for type 2 diabetes, including qualifying cardiovascular or kidney-benefit pathways, while other indications are subject to separate Oscar guidelines.
Definitions
Definitions
ClassOral antidiabetic drugs
MechanismBlock the DPP-4 enzyme responsible for degradation of incretin hormones
Hormones affectedGLP-1 and GIP
Definitions
ClassMedications that imitate the function of incretin hormones
EffectsSlow digestion and prevent the liver from making too much glucose
Insulin effectHelp the pancreas produce more insulin when needed
Preferred Therapy Sequence
Step
Requirement
Coverage criteria
1
Preferred medication(s)
The member must be unable to use, or have tried and failed, preferred medication(s) before the requested therapy.
2
Metformin pathway
The member must be unable to use metformin, or must have adequately tried and failed metformin at a minimum effective dose of 1,500 mg daily for at least 90 days.
Key ActionSubmit documentation showing the member meets the applicable type 2 diabetes criteria, including diagnostic results, prior therapy, clinical response, and absence of prohibited concurrent therapy.
Examples include hypertension, dyslipidemia, smoking, obesity, or family history of premature ASCVD.
CKD pathway: The member has CKD with an eGFR of at least 15 mL/min/1.73 m² and the request is for liraglutide (Victoza), Ozempic (semaglutide) injection, or Trulicity (dulaglutide).eGFR ≥15 mL/min/1.73 m²
No duplicate GLP-1-based therapy:
The requested medication will not be used concomitantly with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.
Fasting plasma glucose improvement:
Fasting plasma glucose levels have improved since initiation of therapy.
Since initiation of therapy
Other individualized glycemic target: The member has achieved another individual glycemic target.
Examples include average blood glucose, reduction in preprandial or postprandial glucose, or time in range in members using continuous glucose monitors.
Cardiovascular or kidney benefit pathway
Eligible agent: The requested agent is liraglutide (Victoza), Ozempic (semaglutide) injection, Rybelsus/Ozempic pill (semaglutide), or Trulicity (dulaglutide).
No DPP-4 combination: The member is not receiving a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in combination with a DPP-4 inhibitor or DPP-4 antidiabetic combination.
No concomitant incretin therapy: The requested medication will not be used concomitantly with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.
Metformin or glycemic-control pathway: The member cannot use metformin or has adequately tried and failed metformin at a minimum effective dose of 1500 mg daily for at least 90 days; or combination therapy is required to achieve glycemic control and HbA1c is ≥7.5%.
Established ASCVD pathway: The member has established ASCVD and the request is for liraglutide, Ozempic injection, Rybelsus/Ozempic pill, or Trulicity.
Multiple cardiovascular-risk-factor pathway: The member has at least two cardiovascular risk factors and the request is for Trulicity or Rybelsus/Ozempic pill.2 or more risk factors
CKD pathway: The member has CKD with eGFR of at least 15 mL/min/1.73 m² and the request is for liraglutide, Ozempic injection, or Trulicity.eGFR ≥15 mL/min/1.73 m²
No prohibited DPP-4 combination: The member is not receiving the GLP-1-based therapy with a DPP-4 inhibitor or DPP-4 antidiabetic combination.
No duplicate GLP-1-based therapy: The requested medication will not be used concomitantly with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.
Reduction in HbA1c since initiation of therapy is documented within the past 6 months.
Within the past 6 months
Target HbA1c attained: The member has attained target HbA1c levels.For example, HbA1c less than 7% or a treating-provider-defined member-specific goal
Improved glycemic control
Fasting plasma glucose improvement: Fasting plasma glucose levels have improved since initiation of therapy.
Other individualized glycemic target: The member has achieved another individual glycemic target, such as improved average blood glucose, reduced preprandial or postprandial glucose, or improved time in range for members using continuous glucose monitors.
Cardiovascular or kidney benefit pathway
Eligible agent: The requested agent is liraglutide (Victoza), Ozempic (semaglutide) injection, Rybelsus/Ozempic pill (semaglutide), or Trulicity (dulaglutide).
No DPP-4 combination: The member is not receiving a GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist in combination with a DPP-4 inhibitor or DPP-4 antidiabetic combination.
No concomitant incretin therapy: The requested medication will not be used concomitantly with another GLP-1 receptor agonist or dual GIP/GLP-1 receptor agonist.
Coding
Diagnostic threshold≥6.5% (≥48 mmol/mol)
TestHemoglobin A1c (HbA1c)
UseOne accepted criterion for diagnosing type 2 diabetes mellitus
Coding
Diagnostic threshold≥200 mg/dL (≥11.1 mmol/L)
Required contextClassic symptoms of hyperglycemia or hyperglycemic crisis
TestRandom plasma glucose
Coding
Minimum dose1500 mg daily
Minimum durationAt least 90 days
PathwayThe member is unable to use, or has adequately tried and failed, metformin
Coding
HbA1c threshold≥7.5%
RequirementCombination therapy is required to achieve glycemic control
UseQualifying initial-therapy pathway for type 2 diabetes mellitus
Coding
Minimum eGFR≥15 mL/min/1.73 m²
ConditionChronic kidney disease
UseQualifying CKD pathway for selected agents
Coding
Required responseReduction in HbA1c
Documentation periodWithin the past 6 months
TimingSince initiation of therapy
Coding
Example targetHbA1c less than 7%
Individualized goalAs determined by the treating provider based on member-specific goals
Continuation useAttainment of target HbA1c levels supports continued therapy
Document type 2 diabetes using at least one of the following: fasting glucose ≥126 mg/dL (≥7.0 mmol/L); 2-hour glucose tolerance test ≥200 mg/dL (≥11.1 mmol/L); HbA1c ≥6.5% (≥48 mmol/mol); or random plasma glucose ≥200 mg/dL (≥11.1 mmol/L) with classic hyperglycemia symptoms or hyperglycemic crisis.
Meet at least one treatment pathway: inability to use or adequate trial and failure of metformin at a minimum effective dose of 1,500 mg daily for at least 90 days; need for combination therapy with HbA1c ≥7.5%; established ASCVD with an eligible requested agent; at least two cardiovascular risk factors with an eligible requested agent; or CKD with eGFR ≥15 mL/min/1.73 m² and an eligible requested agent.
Eligible ASCVD agents: Victoza, Ozempic injection, Rybelsus/Ozempic pill, or Trulicity.
Eligible multiple-risk-factor agents: Trulicity or Rybelsus/Ozempic pill.
Eligible CKD agents: Victoza, Ozempic injection, or Trulicity.
Do not use the requested drug with a DPP-4 inhibitor or DPP-4-containing combination, or concurrently with another GLP-1 or dual GIP/GLP-1 agonist.
Prior Authorization
Reauthorization Requirements
For continued care, document that the member continues to meet a qualifying response or disease-benefit criterion and is not receiving prohibited combination therapy. If criteria are met, reauthorization may be approved for up to 12 months.
Document at least one qualifying outcome: HbA1c reduction since therapy initiation within the past 6 months; attainment of target HbA1c (for example, <7% or a member-specific provider goal); improved fasting plasma glucose; another individual glycemic target such as average glucose, preprandial or postprandial glucose, or CGM time in range; or established ASCVD, multiple cardiovascular risk factors, or CKD with an agent having proven benefit.
Confirm no concurrent DPP-4 inhibitor or DPP-4-containing combination.
Confirm no concurrent use of another GLP-1 or dual GIP/GLP-1 agonist.
Prior Authorization
Annual Continued-Care Authorization
Request annual continued-care authorization only when the subsequent-review criteria are documented. Approval after a successful review is limited to a period of up to 12 months.
Submit current response or qualifying cardiovascular/renal-benefit documentation for review.
Plan for review and renewal at intervals no longer than 12 months.
Step Therapy
Preferred Therapy and Metformin Step
Document the preferred-therapy step and the metformin pathway before requesting coverage. The member must be unable to use or have adequately tried and failed metformin at a minimum effective dose of 1,500 mg daily for at least 90 days, unless another qualifying pathway applies.
Record inability to use or failure of preferred medication(s), when applicable.
Document metformin dose, duration, and outcome; or document the applicable combination-therapy, ASCVD, cardiovascular-risk-factor, or CKD pathway.
For non-formulary products, also apply PG069.
Documentation Required
Clinical and Prior-Treatment Documentation
Include documentation that supports both the diagnosis and prior treatment history. Documentation may consist of current chart notes, relevant test results, imaging reports, prescription claims, and/or prescription receipts.
Provide up-to-date chart notes supporting the diagnosis and requested therapy.
Include relevant laboratory results and imaging reports when applicable.
Use prescription claims or receipts to support trials of formulary alternatives.
Documentation Required
Required Supporting Clinical Information
The initial request must provide sufficient clinical information for the Plan to verify age, type 2 diabetes, the applicable treatment pathway, and safety requirements.
Member age and requested product, including FDA-appropriate age eligibility.
Diagnostic testing: fasting glucose, 2-hour glucose tolerance test, HbA1c, or qualifying random glucose with symptoms or crisis.
Metformin history, including inability to use or trial at ≥1,500 mg daily for ≥90 days, when that pathway is used.
Current HbA1c and, when applicable, HbA1c ≥7.5% supporting required combination therapy.
Documentation of ASCVD, at least two cardiovascular risk factors, or CKD with eGFR ≥15 mL/min/1.73 m² when using those pathways.
Current medication list confirming absence of prohibited DPP-4 or GLP-1-based combinations.
Documentation Required
Continuation-Therapy Response Documentation
For continuation requests, provide objective evidence of benefit since treatment initiation, with relevant response data obtained within the past 6 months.
Document HbA1c reduction, attainment of a target HbA1c, or improvement in fasting plasma glucose.
Alternatively, document another individualized glycemic response, such as average glucose, preprandial or postprandial glucose, or CGM time in range.
If relying on cardiovascular or renal benefit, document established ASCVD, multiple cardiovascular risk factors, or CKD and the qualifying agent.
Documentation Required
Document Continued Clinical Benefit
Document continued clinical benefit since initiation of therapy within the past 6 months. The record should show the member’s current response or the qualifying disease-specific benefit supporting ongoing treatment.
Include current and prior HbA1c values when using HbA1c response.
State the member-specific glycemic target when target attainment is used.
Include current glucose or CGM data when using other glycemic-control measures.
Denial Risk
Initial Medical-Necessity Denial Conditions
An initial request is subject to denial when the member does not meet all applicable medical-necessity requirements for type 2 diabetes.
Deny when age is outside the product’s FDA-appropriate range.
Deny when type 2 diabetes is not supported by an accepted diagnostic criterion.
Deny when none of the qualifying pathways is met: metformin inability or adequate failure, combination therapy with HbA1c ≥7.5%, eligible ASCVD pathway, eligible multiple-risk-factor pathway, or eligible CKD pathway.
Deny when required preferred-medication or non-formulary criteria are not satisfied.
Denial Risk
Prohibited Concurrent Therapy
Do not approve therapy that is used in a prohibited combination with a DPP-4 inhibitor or DPP-4-containing antidiabetic combination, or with another GLP-1 or dual GIP/GLP-1 agonist.
Review the complete medication list before initial authorization and reauthorization.
Discontinue or avoid concurrent DPP-4 inhibitor therapy, including DPP-4 combination products.
Do not use two GLP-1-based or dual GIP/GLP-1 therapies concomitantly.
Denial Risk
Other Indications Are Not Covered Under This Guideline
GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists are not medically necessary under this guideline for indications other than type 2 diabetes mellitus. Such uses are considered experimental, investigational, or unproven.
The guideline does not cover 'type 1.5' diabetes; the prescriber must determine the appropriate primary diabetes diagnosis.
Use PG070 for weight management.
Use PG194 for Wegovy cardiovascular-risk reduction in adults with established cardiovascular disease and obesity or overweight, or for MASH.
Use PG255 for Zepbound treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.
Use PG276 for the corresponding Zepbound obstructive-sleep-apnea indication for members in New York.
Denial Risk
Reauthorization Denial Conditions
A reauthorization request is subject to denial when continued benefit or another qualifying continuation criterion is not demonstrated, or when prohibited combination therapy is present.
Deny when there is no documented HbA1c reduction, target HbA1c attainment, improved glycemic control, or qualifying ASCVD, cardiovascular-risk-factor, or CKD benefit.
Deny when the requested therapy is used with a DPP-4 inhibitor or DPP-4-containing combination.
Deny when the requested therapy is used with another GLP-1 or dual GIP/GLP-1 agonist.
Ensure response documentation is current and supports benefit since initiation within the past 6 months.
Denial Risk
Non-Covered and Unproven Indications
Uses for weight management, cardiovascular-risk reduction, MASH, obstructive sleep apnea, or other indications outside type 2 diabetes are not covered as medically necessary under this guideline and may be considered experimental, investigational, unproven, or not medically necessary.
Coverage for obesity treatment, weight loss, weight reduction, or dietary control depends on the member’s benefit plan and applicable separate guideline.
Refer weight-management requests to PG070.
Refer eligible Wegovy cardiovascular-risk-reduction or MASH requests to PG194.
Refer Zepbound obstructive-sleep-apnea requests to PG255, or to PG276 for New York members.
Do not treat 'type 1.5' diabetes as an established covered indication under this guideline; determine the appropriate primary diagnosis.
Definitions
DefinitionA metabolic disorder characterized by insufficient insulin production or insulin resistance in the body cells
Common managementLifestyle changes and non-insulin medications
Additional treatmentInsulin injections may be used if necessary
Definitions
DefinitionA blood test that measures average blood glucose levels over the past 2 to 3 months
Alternative namesA1C or glycosylated hemoglobin test
Result considerationsAge, ethnicity, certain conditions, and pregnancy can affect A1C results
Definitions
DefinitionWritten information supporting diagnoses or prior trials of formulary alternatives
Clinical recordsUp-to-date chart notes, relevant test results, and relevant imaging reports
Prior-treatment recordsPrescription claims records and/or prescription receipts